Stock TECH BIO-TECHNE CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

News Bio-Techne Corporation

Equities

TECH

US09073M1045

Delayed Nasdaq
Other stock markets
 03:51:18 2024-05-28 pm EDT 		5-day change 1st Jan Change
79.34 USD -1.79% Intraday chart for Bio-Techne Corporation -4.09% +2.77%
May. 22 Citigroup Downgrades Bio-Techne to Neutral From Buy, With $85 Price Target MT
May. 16 Bio-techne Insider Sold Shares Worth $335,377, According to a Recent SEC Filing MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BIO-TECHNE TO PRESENT AT THE 2024 LEERINK PARTNERS HEALTHCARE CROSSROADS CONFERENCE
PR
BIO-TECHNE HIGHLIGHTS RECENTLY ANNOUNCED TOP-LINE BIOMARKER DATA FROM PARTNER, REGULUS THERAPEUTICS, USING THE COMPANY'S PROPRIETARY TECHNOLOGY
PR
Citigroup Downgrades Bio-Techne to Neutral From Buy, With $85 Price Target
MT
Bio-techne Insider Sold Shares Worth $335,377, According to a Recent SEC Filing
MT
Transcript : Bio-Techne Corporation Presents at Bank of America Health Care Conference 2024, May-14-2024 02:20 PM
Ex-dividend day
FA
BIO-TECHNE TO PRESENT AT THE BofA SECURITIES HEALTH CARE CONFERENCE 2024
PR
Argus Adjusts Price Target on Bio-Techne to $95 From $90, Keeps Buy Rating
MT
UBS Adjusts Price Target on Bio-Techne to $90 From $80, Maintains Buy Rating
MT
Leerink Partners Adjusts Price Target on Bio-Techne to $95 From $85
MT
Scotiabank Adjusts Price Target on Bio-Techne to $83 From $80
MT
RBC Capital Adjusts Price Target on Bio-Techne to $72 From $71, Sector Perform Rating Kept
MT
Baird Adjusts Bio-Techne Price Target to $81 From $73
MT
Equity Markets Mostly Fall After Fed Leaves Rate Unchanged
MT
Equity Markets Mostly Fall After Fed Leaves Rate Unchanged
MT
Top Midday Gainers
MT
US Equity Indexes Mixed as Investors Look for Clarity in Fed's Policy Path in Presidential Election Year
MT
US Equity Indexes Mixed Ahead of Fed Policy Statement, Views on Monetary Policy Path for 2024
MT
Bio-Techne Shares Jump After Fiscal Q3 Beat
MT
Deutsche Bank Adjusts Price Target on Bio-Techne to $84 From $82
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TECH Stock
  4. News Bio-Techne Corporation